GDF-8
Endogenous myostatin (GDF-8) pathway object — inhibitor drugs ≠ administering myostatin; no PE glow.
Editorial review:Evidence snapshot
This drawer marks papers. It is not a plan, a dose, or a source. A paper is a bounded report. It is not a protocol. Grades name the object. They are not a safety rating.
Identity lock. GDF-8 (growth/differentiation factor 8; common name myostatin) is a TGF-β superfamily ligand that negatively regulates skeletal-muscle mass (UniProt O14793; human precursor length 375 aa). It is an endogenous protein, not a “peptide vial therapy.” Educational object here is the protein and its pathway — discovery biology, structure with follistatin-288, and the clinical development status of pathway inhibitors (antibodies / ligand traps). Pathway-inhibitor drugs are different objects from “myostatin” itself. PubChem has no clean small-molecule CID for the protein. This drawer marks papers. It is not use advice.
Bottom line
Myostatin discovery and mechanism reviews are mature. Clinical translation has focused on inhibitors (e.g. bimagrumab / ActRII blockade and related programs) for muscle loss, obesity-adjunct fat-mass reduction, and neuromuscular disease — with mixed Phase 2/3 trajectories that must be graded as inhibitor-drug evidence, not as proof for administering GDF-8 protein. There is no educational case for “taking myostatin.” Refuse performance-enhancement glow for gray-market “myostatin” or vague “myostatin-blocker peptide” products.
Papers
Discovery / mechanism (the protein)
PMID 9139826 — McPherron 1997
Tested: identification of myostatin as a TGF-β family regulator of skeletal muscle mass in mice (foundational discovery).
Does not show: a human therapeutic product or a rationale to administer GDF-8 protein.
PMID 10508689 — Lee 1999
Tested: early synthesis of myostatin biology and control of skeletal muscle mass.
Does not show: an approved human myostatin drug.
PMID 11459935 — Lee 2001
Tested: regulation of myostatin activity and muscle growth (pathway mechanistic framing).
Does not show: clinical approval of an inhibitor class.
PMID 19644449 — Cash 2009
Tested: structure of myostatin bound to follistatin-288.
Does not show: human clinical efficacy for any inhibitor.
PMID 26305594 — Sharma 2015
Tested: review expanding myostatin horizons beyond classic muscle-mass control.
Does not show: new pivotal trial data.
PMID 36266260 — Lee 2023
Tested: contemporary physiologic review of myostatin as a skeletal-muscle chalone.
Does not show: that pathway reviews equal approved consumer products.
PMID 33938454 — Lee 2021
Tested: review targeting the myostatin pathway for muscle loss and metabolic dysfunction.
Does not show: automatic success of every inhibitor in the pipeline.
PMID 34520530 — Rodgers 2022
Tested: Endocrine Reviews synthesis of myostatin/activin receptor ligands and development status of attenuating drugs.
Does not show: interchangeability of all ActRII / myostatin-pathway agents.
Pathway inhibitors — clinical (different objects; context only)
PMID 33439265 — Heymsfield 2021
Tested: Phase 2 RCT of bimagrumab vs placebo on body fat mass in adults with type 2 diabetes and obesity (ActRII antibody — not GDF-8 protein).
Does not show: efficacy of administering myostatin, or approval of unlabeled “myostatin blockers.”
PMID 41772149 — Heymsfield 2026
Tested: randomized Phase 2 of bimagrumab plus semaglutide (combination obesity framing).
Does not show: a GDF-8 protein indication; inhibitor-drug object only.
PMID 36527600 — Petricoul 2023
Tested: clinical pharmacokinetics/pharmacodynamics of bimagrumab.
Does not show: myostatin-protein therapy evidence.
What is not established
Any medical or performance rationale for administering GDF-8 / myostatin protein. That inhibitor-drug trials grade gray-market “myostatin” or anonymous “myostatin-blocker peptides.” That every ActRII / activin-pathway agent is interchangeable with selective myostatin neutralization. Product identity for unregulated preparations claiming myostatin activity. This drawer does not provide use advice, schedules, or sourcing.
Selected sources
9139826 10508689 11459935 19644449 26305594 36266260 33938454 34520530 33439265 41772149 36527600
Reported experiences
Reported topics are not established benefits.Risks and unknowns
Compare experiences with care.
Join the discussion
Verified members can contribute to compound conversations.